With twenty years of deal-making experience spanning small biotech and Big Pharma, Dr. Angèle Maki is Chief Business Officer of Hummingbird Bioscience, a clinical-stage biotechnology company with proprietary and differentiated Rational Antibody Discovery (RAD) and dual-payload ADC platforms, developing therapeutics for the treatment of cancer. Prior to Hummingbird, Angèle held business development roles with increasing responsibility starting at Medarex followed by Bristol Myers Squibb (which acquired Medarex), Genentech, 23andMe, Merck & Co, Eli Lilly, and ReCode. During her career, she has successfully led diligence and negotiations for numerous in- and out-licensing transactions, from early-stage research technologies to clinical-stage assets. She was also a key player within the corporate venture arm of Lilly. Angèle has a Ph.D. in biological chemistry from Stanford University and a B.Sc. in chemistry from the University of Winnipeg in Canada.